Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:04:10 EST Sat 13 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Z:LLY - ELI LILLY AND COMPANY - https://www.lilly.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LLY - Z0.41,028.90·1,043.870.11,027.51+18.731.93,274.53,335,39381,0021,008.76  1,028.90  1,003.501,111.99  623.78919:59:3511:4515 min RT 2¢

Recent Trades - Last 10 of 81002
Time ETExPriceChangeVolume
19:59:35Z1,029.0019.6210
19:59:14Z1,028.9519.572
19:59:14Z1,028.9019.5210
19:58:58Z1,029.4820.101
19:58:56Z1,028.9519.571
19:58:43Z1,029.1919.811
19:58:26Z1,029.1919.811
19:58:25Z1,029.0019.6230
19:58:25Z1,029.0019.6210
19:58:05Z1,029.353619.97365

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-12 11:45U:LLYNews ReleaseUpdated data for Lilly's Inluriyo(TM) (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio(TM) (abemaciclib) in ER+, HER2- advanced breast cancer
2025-12-11 06:45U:LLYNews ReleaseLilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
2025-12-09 15:30U:LLYNews ReleaseLilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
2025-12-09 08:28U:LLYNews ReleaseLilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
2025-12-09 07:30U:LLYNews ReleaseLilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naive CLL/SLL
2025-12-08 14:05U:LLYNews ReleaseLilly declares first-quarter 2026 dividend
2025-12-08 10:00U:LLYNews ReleaseCarolyn Bertozzi returns to Lilly board of directors
2025-12-07 16:30U:LLYNews ReleaseLilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
2025-12-03 12:59U:LLYNews ReleaseU.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
2025-11-24 16:30U:LLYNews ReleaseLilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
2025-11-24 12:00U:LLYNews ReleaseLilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
2025-11-19 06:45U:LLYNews ReleaseLilly announces plans to open Lilly Gateway Labs site in Philadelphia
2025-11-18 10:00U:LLYNews ReleaseLilly to participate in Citi's 2025 Global Healthcare Conference
2025-11-10 09:12U:LLYNews ReleaseQueer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
2025-11-06 16:05U:LLYNews ReleaseLilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth
2025-11-06 13:54U:LLYNews ReleaseLilly and U.S. government agree to expand access to obesity medicines to millions of Americans
2025-11-06 06:45U:LLYNews ReleaseLilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
2025-11-03 08:30U:LLYNews ReleaseLilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
2025-10-30 06:45U:LLYNews ReleaseLilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
2025-10-29 10:30U:LLYNews ReleaseLilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States